The Supreme Court’s Albrecht Decision: Unclear Implications for Adverse Reaction Warnings

Elie Biel authored an article for Minnesota Physician regarding a decision by the Supreme Court of the United States to remand a pharmaceutical labeling case to a lower court for future proceedings. The article discusses the litigation surrounding the prescription drug Fosamax, with a focus on the whether the state-based failure-to-warn claim was barred by federal law. Biel further discusses the long-term implications of the decision, highlighting potential areas of concern for future litigants.